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INTRODUCTION: Human mesenchymal 
stem cells (MSCs) are multipotent cells and 
have emerged as a promising tool for clinical 
applications. More than 40 years ago, Hayflick 
discovered that in vitro cultured cells, after a 
given number of divisions, become senescent 
[1]. Senescence also concerns MSCs, which, 
due to limited sample size, may have to be 
expanded in vitro to large extent for clinical 
use. From tissue engineering perspective, the 
senescence of expanded MSCs has certain 
implications, such as quality control and setting 
correct point for differentiation start. Mainly 
because of patient variability, it is unclear to 
what extend cell expansion can proceed for 
each case before the MSCs start to lose their 
ability to differentiate and whether senescing 
MSCs lose this ability gradually or as a discrete 
event [2]. Our aim was to develop a tool based 
on a set of parameters which can predict a 
future loss of differentiation capacity in order 
to provide optimal therapy andprevent waste. 
METHODS: We assessed the senescence of 
hMSCs by monitoring cell division rate, colony 
forming units, senescence-associated beta-
galactosidase activity and expression levels of 
three senescence-associated marker genes 
(CDC2, TOP2A and p53) across passages. This 
data was correlated to differentiation to 
chondrogenic phenotype of hMSCs cultured in 
3-dimensional biodegradable scaffolds. 
Chondrogenesis of the constructs was assessed 
by RT-PCR (Aggrecan, Collagen Type II), 
immunoblotting as well as histological and 
immunohistochemical stainings. 
RESULTS: Analysis of the data showed that 
hMSCs undergo in vitro senescence (Figure 1) 
which reduces their ability to differentiate 
(Figure 2). Senescence can be assessed by 
several markers but not a single one of them is 
‘fool proof’. Therefore, it makes sense to 
combine two or more markers in a battery of 
tests in order to predict excessive loss of 
potential to undergo chondrogenesis. 
 
Fig. 1: Percentage of senescent cells among 
passages. *, P<0.05 (paired Student’s test). 
 
Fig. 2: Normalized expression of collagen type 
II after 30 days in chondrogenic medium, 
compared to control medium. 
 
DISCUSSION & CONCLUSIONS: We 
demonstrated that it is possible to correlate 
senescence to differentiation at an earlier point 
when cells still can be used to their full 
potential. On practical level, it is worth 
cryopreserving consecutive passages and - once 
senescence evaluation accomplished - to use 
the appropriate ones for further differentiation. 
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